Primary Epstein–Barr virus infection, seroconversion, and post‐transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study

Abstract

The incidence of PTLD in renal transplants ranges from 0.5% to 2.9%. Our data show a significantly higher rate in EBV-seronegative renal allograft recipients, suggesting the need for close surveillance. Our data also suggest that donors for EBV-seronegative recipients may be accepted irrespective of positive or negative serostatus, with ongoing surveillance important in either circumstance.